Reduction of serum prostate-specific antigen levels following varicella-zoster infection and valaciclovir treatment in prostate cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19278776.
- Also identified by DOI 10.1016/j.eururo.2009.02.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present two prostate cancer patients, including one with a castration-resistant cancer whose rising serum prostate-specific antigen (PSA) levels showed a remarkable drop after a reactivated varicella-zoster virus infection treated with valaciclovir. In one patient, we found a temporary decrease in serum PSA lasting for at least 4 mo. In the patient with castration-resistant prostate cancer, serum PSA decreased to <0.01 microg/l and has remained undetectable since.
Medical subject headings
- Acyclovir
- Antiviral Agents
- Herpes Zoster
- Prostate-Specific Antigen
- Prostatic Neoplasms
- Valine